about
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceAutophagy in acute leukemias: a double-edged sword with important therapeutic implicationsThe emerging multiple roles of nuclear AktPotential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disordersSubnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell linesTherapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Nuclear inositol lipid metabolism: more than just second messenger generation?Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.GSK-3β: a key regulator of breast cancer drug resistance.The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Nuclear phosphoinositides and their roles in cell biology and disease.Targeting the cancer initiating cell: the ultimate target for cancer therapy.Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology.Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).Current treatment strategies for inhibiting mTOR in cancer.Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered laminsIncreased NGAL (Lnc2) expression after chemotherapeutic drug treatment.Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts.Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta.TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest.Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry.Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
P50
Q24645668-E64B4AF2-6954-45FE-8FD2-1A7DFB2D9BF5Q26828544-C9B2F81B-9C3A-4C3D-AAAD-4972379716FBQ26865922-AB5FD361-ECC9-4346-B642-72C4973817E4Q28067037-7F793E69-5965-407F-899A-775809DBA875Q33253399-A1694DFE-92FA-45A9-A774-F5C5E487A698Q33493174-A3892357-8057-4F63-BA73-3454D80BBF2AQ33618630-B156015C-3049-4697-85B7-39B2A2024D38Q33952803-4B5406E5-2B43-4F9D-91DB-4D59D9421031Q34024558-DA5B8B78-CE7D-42DA-9C53-EB51CF4CE4E3Q34173253-9E6EEB62-C64E-4F20-A029-2A5FFF774A19Q34260622-1B8E0F9F-E87B-4AA3-B3CE-6B7C49E34416Q36223200-110CEBB4-ED7B-47DC-8A6F-FD6B480EFE73Q36461618-9CD676AE-02FA-4E5A-8007-01BFCD3503ADQ36738818-BE69F930-28B9-40AA-B448-AB45BE7C6523Q37360025-00AAD99F-FDD8-4E0D-B29F-82A462E24566Q37692574-D7A17A8B-4D7E-4BF2-BA72-89BC634D6E91Q37732880-EE2AD6FF-0C5C-4524-8100-8C721C85C4C3Q37865381-7C655451-0D56-4F9E-9103-367857461636Q37931279-B2D1553F-B3A1-4FAF-AA69-E0E1BB08206AQ37990970-D3558DF9-8FFE-4C10-97BF-0BA1B7A2958AQ38017727-F46EC38C-762D-4C44-B911-2D0501BD4445Q38113583-658A5407-2B9C-43EE-91D3-AC9971971E85Q38166578-485F6684-65F4-4306-B38E-40686318E164Q38211159-B83051A5-799B-49D6-A472-7A1FE4FDA624Q38223508-3BC14133-FAE7-457E-9734-CC1D21B2847BQ38286529-D8DAFD97-DCE3-42B1-85B8-11C83E3BC073Q38579553-96EC8340-25F5-4929-AF98-454F80C2C0F6Q38893099-C58D7032-93C3-4E03-846C-C0F5200EBB84Q39257895-ACEF76F1-7626-449A-83F3-44C27A4D2CCAQ39344848-4D6D5BE2-6640-473C-9033-CF410190E636Q39590044-8A2AE108-4151-4B05-BFF0-48EA77C7A4FFQ39650704-E9E9831F-30E9-4BC8-9C97-323F3279AC45Q39653305-ED713C3F-BFB0-4EB9-B2CE-9064EE52C696Q40135086-E08C1761-7EFC-4744-A979-17E91797CF08Q40154931-BE944354-E6B8-43E4-82AE-AC391336D297Q43214385-08C8988B-3A6D-448C-95BF-049B4533A79EQ46099348-50C80449-D3BB-4EC1-802C-BD0EE749514FQ47754054-32EBAF50-5579-45D5-8C6C-1DDE72D37F76Q48560277-7ADD1B58-E09C-43D9-90C8-CBFEEC2CA7ADQ56378380-9350F88C-9F2D-43B1-9277-7D196919794F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Camilla Evangelisti
@ast
Camilla Evangelisti
@en
Camilla Evangelisti
@es
Camilla Evangelisti
@nl
type
label
Camilla Evangelisti
@ast
Camilla Evangelisti
@en
Camilla Evangelisti
@es
Camilla Evangelisti
@nl
prefLabel
Camilla Evangelisti
@ast
Camilla Evangelisti
@en
Camilla Evangelisti
@es
Camilla Evangelisti
@nl
P106
P21
P31
P496
0000-0003-3531-9540